Becton, Dickinson and Company (NYSE:BDX) Rating Lowered to "Hold" at Zacks Research

Becton, Dickinson and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) was downgraded by research analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued on Thursday, Zacks reports.

A number of other research firms have also issued reports on BDX. Weiss Ratings raised Becton, Dickinson and Company from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, November 4th. Barclays upped their price objective on Becton, Dickinson and Company from $165.00 to $195.00 and gave the company an "underweight" rating in a research note on Tuesday, November 10th. Jefferies Financial Group reaffirmed a "buy" rating and set a $242.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, November 5th. TD Cowen increased their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a "sector perform" rating in a research note on Friday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Hold" and a consensus target price of $197.47.

Check Out Our Latest Analysis on BDX

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $212.19 on Thursday. Becton, Dickinson and Company has a 1-year low of $140.11 and a 1-year high of $220.36. The stock has a market cap of $58.47 billion, a PE ratio of 51.25, a price-to-earnings-growth ratio of 3.63 and a beta of 0.22. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.87 and a quick ratio of 0.54. The firm has a fifty day moving average price of $194.40 and a 200 day moving average price of $170.85.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.08. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. Becton, Dickinson and Company's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $3.96 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 13.21 EPS for the current year.

Becton, Dickinson and Company announced that its board has approved a stock repurchase plan on Thursday, November 5th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to purchase up to 3.6% of its stock through open market purchases. Share repurchase plans are usually a sign that the company's management believes its shares are undervalued.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $23,134,230. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the firm's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 3,310 shares of company stock worth $688,650. Company insiders own 0.40% of the company's stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Large investors have recently made changes to their positions in the stock. Defiance ETFs LLC purchased a new position in Becton, Dickinson and Company in the 3rd quarter valued at approximately $224,000. Kestra Advisory Services LLC boosted its position in Becton, Dickinson and Company by 616.1% during the third quarter. Kestra Advisory Services LLC now owns 89,336 shares of the medical instruments supplier's stock worth $15,991,000 after purchasing an additional 76,861 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in Becton, Dickinson and Company during the third quarter worth $1,002,000. Auxier Asset Management LLC boosted its position in Becton, Dickinson and Company by 1.1% during the third quarter. Auxier Asset Management LLC now owns 17,919 shares of the medical instruments supplier's stock worth $3,208,000 after purchasing an additional 200 shares in the last quarter. Finally, Innovator Capital Management LLC acquired a new stake in Becton, Dickinson and Company in the third quarter valued at $2,709,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD's products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Featured Stories

Analyst Recommendations for Becton, Dickinson and Company (NYSE:BDX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Becton, Dickinson and Company Right Now?

Before you consider Becton, Dickinson and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.

While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines